Emergent BioSolutions Breaks Ground on New Project
Five weeks after announcing a planned $108 million expansion in Lansing, Emergent BioSolutions has broken ground on the first phase of the project. Participants gathered Tuesday afternoon at the pharmaceutical company’s facility in North Lansing. The ceremony launched construction of a $9 million administration building and infrastructure upgrades.
Adam Havey, Executive Vice President of Emergent’s BioDefense Division, says the impact will be noticeable.
“It’ll, I think, really change the look and feel of Emergent from the outside, from a campus perspective," he said. "You know, it’ll be very aesthetically pleasing and very secure, which we’ve always been.”
The Maryland-based company—which employs 436 people locally--manufactures the country’s only federally-approved anthrax vaccine at their facility on North Martin Luther King Boulevard.